Tango Rally

Tango Therapeutics (NASDAQ:TNGX) rallied 52.15 % week‑on‑week, largely after Stifel upgraded the stock to a “buy” and confirmed a $15 price target. The surge coincides with the launch of several clinical trials for its pancreatic cancer candidate vopimetostat, now being tested in combination with multiple inhibitors. A key partnership has been formed with Erasca, which will jointly evaluate vopimetostat alongside Erasca’s ERAS‑0015 in pancreatic cancer patients, adding depth to the company’s pipeline and potentially accelerating future growth.